Clearly, the FDA and the life science industry recognize the importance of high-quality clinical trial data, which can only be achieved by clinical trial processes that represent all patients. The failure stanozolol dose to do so can mean the discovery of significant adverse effects in some patient subsets after approvals, including impairment and death, and can result in the medical product loosing FDA approval and, hence, removal from the medical marketplace